| 000 | 01057 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513200609.0 | ||
| 264 | 0 | _c20000211 | |
| 008 | 200002s 0 0 eng d | ||
| 022 | _a1381-6128 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRewinkel, J B | |
| 245 | 0 | 0 |
_aStrategies and progress towards the ideal orally active thrombin inhibitor. _h[electronic resource] |
| 260 |
_bCurrent pharmaceutical design _cDec 1999 |
||
| 300 |
_a1043-75 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAmidines _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xpharmacology |
| 650 | 0 | 4 |
_aGuanidine _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aThrombin _xantagonists & inhibitors |
| 700 | 1 | _aAdang, A E | |
| 773 | 0 |
_tCurrent pharmaceutical design _gvol. 5 _gno. 12 _gp. 1043-75 |
|
| 999 |
_c10563834 _d10563834 |
||